{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:16:11Z","timestamp":1790244971955,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurochemistry International"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.neuint.2016.06.008","type":"journal-article","created":{"date-parts":[[2016,6,19]],"date-time":"2016-06-19T16:52:28Z","timestamp":1466355148000},"page":"103-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Augmentation of antidepressant effects of venlafaxine by agomelatine in mice are independent of kynurenine pathway"],"prefix":"10.1016","volume":"99","author":[{"given":"Jaya","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Khanam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1852-9191","authenticated-orcid":false,"given":"Divya","family":"Vohora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuint.2016.06.008_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-12-398314-5.00002-7","article-title":"Inflammation-related disorders in the tryptophan catabolite pathway in depression and somatization","volume":"88","author":"Anderson","year":"2012","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"10.1016\/j.neuint.2016.06.008_bib2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.pnpbp.2005.04.032","article-title":"Antidepressant action of agomelatine (S 20098) in a transgenic mouse model","volume":"29","author":"Barden","year":"2005","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuint.2016.06.008_bib3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0022-3956(96)00029-5","article-title":"A\u00a0randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia","volume":"30","author":"Benkert","year":"1996","journal-title":"J.\u00a0Psychiatr. Res."},{"key":"10.1016\/j.neuint.2016.06.008_bib4","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/FBP.0b013e3280116e5c","article-title":"Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model","volume":"17","author":"Bertaina-Anglade","year":"2006","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuint.2016.06.008_bib5","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1038\/tp.2014.125","article-title":"Hippocampal and behavioral dysfunctions in a mouse model of environmental stress: normalization by agomelatine","volume":"4","author":"Boulle","year":"2014","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuint.2016.06.008_bib6","first-page":"126","article-title":"Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors","volume":"29","author":"Bourin","year":"2004","journal-title":"J.\u00a0Psychiatry Neurosci."},{"key":"10.1016\/j.neuint.2016.06.008_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2014.00012","article-title":"Kynurenines in CNS disease: regulation by inflammatory cytokines","volume":"8","author":"Campbell","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuint.2016.06.008_bib8","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.neubiorev.2005.03.009","article-title":"The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice","volume":"29","author":"Cryan","year":"2005","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.neuint.2016.06.008_bib9","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.genhosppsych.2013.09.001","article-title":"Successful use of agomelatine and venlafaxine combination in major depression","volume":"36","author":"Dahale","year":"2014","journal-title":"General Hosp. psychiatry"},{"key":"10.1016\/j.neuint.2016.06.008_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/YIC.0b013e32834ce13f","article-title":"Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies","volume":"27","author":"de Silva","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuint.2016.06.008_bib12","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.pnpbp.2007.02.008","article-title":"Involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of venlafaxine in mice","volume":"31","author":"Dhir","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuint.2016.06.008_bib13","first-page":"201","article-title":"Modulation of microglial function by the antidepressant drug venlafaxine","volume":"7","author":"Dubovicky","year":"2014","journal-title":"Interdiscip. Toxicol."},{"key":"10.1016\/j.neuint.2016.06.008_bib14","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jad.2011.04.025","article-title":"Moderating effect of indoleamine 2, 3-dioxygenase (IDO) activation in the association between depressive symptoms and carotid atherosclerosis: evidence from the Young Finns study","volume":"133","author":"Elovainio","year":"2011","journal-title":"J.\u00a0Affect Disord."},{"key":"10.1016\/j.neuint.2016.06.008_bib15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.neuroscience.2013.04.060","article-title":"Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications","volume":"246","author":"Felger","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuint.2016.06.008_bib16","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1469-7610.2010.02245.x","article-title":"The possible role of the kynurenine pathway in adolescent depression with melancholic features","volume":"51","author":"Gabbay","year":"2010","journal-title":"J.\u00a0Child. Psychol. Psychiatry"},{"key":"10.1016\/j.neuint.2016.06.008_bib17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2174\/1570159X12999140619122914","article-title":"Agomelatine in the treatment of major depressive disorder: an assessment of benefits and risks","volume":"12","author":"Gahr","year":"2014","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuint.2016.06.008_bib18","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.4088\/JCP.08m04548","article-title":"Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial","volume":"70","author":"Goodwin","year":"2009","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuint.2016.06.008_bib19","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/rheumatology\/33.10.927","article-title":"Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity","volume":"33","author":"Gratacos","year":"1994","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.neuint.2016.06.008_bib20","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1111\/bph.12720","article-title":"Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties","volume":"171","author":"Guardiola-Lemaitre","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuint.2016.06.008_bib21","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/archpsyc.62.10.1097","article-title":"Epidemiology of major depressive disorder: results from the national epidemiologic survey on alcoholism and related conditions","volume":"62","author":"Hasin","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuint.2016.06.008_bib22","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.pnpbp.2007.11.024","article-title":"Aripiprazole as an adjunctive treatment for refractory unipolar depression","volume":"32","author":"Hellerstein","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuint.2016.06.008_bib23","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/0004867414525837","article-title":"Comparison of agomelatine and selective serotonin reuptake inhibitors\/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials","volume":"48","author":"Huang","year":"2014","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.neuint.2016.06.008_bib25","first-page":"1307","article-title":"Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial","volume":"11","author":"Kang","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.neuint.2016.06.008_bib26","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1177\/0960327112472994","article-title":"Agomelatine: an antidepressant with new potent hepatoprotective effects on paracetamol-induced liver damage in rats","volume":"32","author":"Karakus","year":"2013","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.neuint.2016.06.008_bib27","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1017\/S1461145705005316","article-title":"Involvement of nitric oxide-cGMP pathway in the antidepressant-like effects of adenosine in the forced swimming test","volume":"8","author":"Kaster","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuint.2016.06.008_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1300\/J092v06n02_04","article-title":"Comparative study of antidepressants and herbal psychotropic drugs in a mouse model of chronic fatigue","volume":"6","author":"Kaur","year":"2000","journal-title":"J.\u00a0Chronic Fatigue Syndrome"},{"key":"10.1016\/j.neuint.2016.06.008_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.euroneuro.2005.09.002","article-title":"Placebo-controlled trial of agomelatine in the treatment of major depressive disorder","volume":"16","author":"Kennedy","year":"2006","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"Suppl.\u00a02","key":"10.1016\/j.neuint.2016.06.008_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/11318660-000000000-00000","article-title":"Agomelatine efficacy at each phase of antidepressant treatment","volume":"23","author":"Kennedy","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuint.2016.06.008_bib31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/JCP.0b013e318172b48c","article-title":"A\u00a0double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR","volume":"28","author":"Kennedy","year":"2008","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.neuint.2016.06.008_bib32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/11534420-000000000-00000","article-title":"Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness","volume":"24","author":"Kennedy","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuint.2016.06.008_bib33","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","article-title":"The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)","volume":"289","author":"Kessler","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.neuint.2016.06.008_bib34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1017\/S0033291709990213","article-title":"Age differences in major depression: results from the national comorbidity survey replication (NCS-R)","volume":"40","author":"Kessler","year":"2010","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuint.2016.06.008_bib35","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1172\/JCI61884","article-title":"Brain indoleamine 2, 3-dioxygenase contributes to the comorbidity of pain and depression","volume":"122","author":"Kim","year":"2012","journal-title":"J.\u00a0Clin. investigation"},{"key":"10.1016\/j.neuint.2016.06.008_bib36","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.pnpbp.2010.08.026","article-title":"In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression","volume":"35","author":"Kubera","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuint.2016.06.008_bib37","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0889-1591(02)00014-4","article-title":"The enzyme indoleamine 2,3-dioxygenase is induced in the mouse brain in response to peripheral administration of lipopolysaccharide and superantigen","volume":"16","author":"Lestage","year":"2002","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuint.2016.06.008_bib38","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1017\/S1461145710001045","article-title":"The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT(2C) receptors","volume":"14","author":"Millan","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuint.2016.06.008_bib39","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/sj.mp.4002006","article-title":"The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression","volume":"12","author":"M\u00fcller","year":"2007","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuint.2016.06.008_bib40","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1017\/S1461145709990514","article-title":"Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor-impaired mice","volume":"13","author":"Paizanis","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuint.2016.06.008_bib41","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/sj.npp.1300091","article-title":"Effect of agomelatine in the chronic mild stress model of depression in the rat","volume":"28","author":"Papp","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuint.2016.06.008_bib42","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1517\/14656561003614781","article-title":"Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era","volume":"11","author":"Philip","year":"2010","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.neuint.2016.06.008_bib43","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/15622970802573246","article-title":"Pro-inflammatory biomakers in depression: treatment with venlafaxine","volume":"10","author":"Piletz","year":"2009","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.neuint.2016.06.008_bib44","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2147\/PPA.S42789","article-title":"Efficacy and tolerability of agomelatine in the treatment of depression","volume":"8","author":"Plesnicar","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.neuint.2016.06.008_bib45","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.neuint.2016.06.008_bib46","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.psyneuen.2014.03.013","article-title":"Does tryptophan degradation along the kynurenine pathway mediate the association between pro-inflammatory immune activity and depressive symptoms?","volume":"45","author":"Quak","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuint.2016.06.008_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002130050638","article-title":"Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity","volume":"138","author":"Redrobe","year":"1998","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuint.2016.06.008_bib48","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jpsychires.2015.05.007","article-title":"Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: evidences from animal and human studies","volume":"68","author":"Reus","year":"2015","journal-title":"J.\u00a0Psychiatr. Res."},{"key":"10.1016\/j.neuint.2016.06.008_bib49","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0166-4328(03)00069-X","article-title":"Involvement of NMDA receptors and L-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice","volume":"144","author":"Rosa","year":"2003","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuint.2016.06.008_bib50","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1192\/bjp.180.5.396","article-title":"Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis","volume":"180","author":"Smith","year":"2002","journal-title":"Br. J. psychiatry"},{"key":"10.1016\/j.neuint.2016.06.008_bib51","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00428203","article-title":"The tail suspension test: a new method for screening antidepressants in mice","volume":"85","author":"Steru","year":"1985","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuint.2016.06.008_bib52","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1365\/s10337-008-0879-9","article-title":"Determination of 5-hydroxytryptamine, norepinephrine, dopamine and their metabolites in rat brain tissue by LC\u2013ESI\u2013MS\u2013MS","volume":"69","author":"Su","year":"2009","journal-title":"Chromatographia"},{"key":"10.1016\/j.neuint.2016.06.008_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g1888","article-title":"Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies","volume":"348","author":"Taylor","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.neuint.2016.06.008_bib54","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.bbi.2011.12.011","article-title":"A\u00a0comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia","volume":"26","author":"Tynan","year":"2012","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuint.2016.06.008_bib55","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1021\/jm0201159","article-title":"Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists","volume":"45","author":"Uchikawa","year":"2002","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuint.2016.06.008_bib56","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jad.2016.03.048","article-title":"Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg\/day) and escitalopram (10-20mg\/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study","volume":"199","author":"Udristoiu","year":"2016","journal-title":"J.\u00a0Affect Disord."},{"key":"10.1016\/j.neuint.2016.06.008_bib57","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1176\/appi.ajp.2007.06071225","article-title":"Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report","volume":"164","author":"Warden","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuint.2016.06.008_bib58","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00008877-200305000-00005","article-title":"A\u00a0comparison of drug effects in latent inhibition and the forced swim test differentiates between the typical antipsychotic haloperidol, the atypical antipsychotics clozapine and olanzapine, and the antidepressants imipramine and paroxetine","volume":"14","author":"Weiner","year":"2003","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuint.2016.06.008_bib59","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/npp.2011.277","article-title":"Interleukin-1beta: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis","volume":"37","author":"Zunszain","year":"2012","journal-title":"Neuropsychopharmacology"}],"container-title":["Neurochemistry International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018616301577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018616301577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T23:58:00Z","timestamp":1536623880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197018616301577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":57,"alternative-id":["S0197018616301577"],"URL":"https:\/\/doi.org\/10.1016\/j.neuint.2016.06.008","relation":{},"ISSN":["0197-0186"],"issn-type":[{"value":"0197-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Augmentation of antidepressant effects of venlafaxine by agomelatine in mice are independent of kynurenine pathway","name":"articletitle","label":"Article Title"},{"value":"Neurochemistry International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuint.2016.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}